Free Trial
LON:AKR

Akers Biosciences (AKR) Share Price, News & Analysis

Akers Biosciences logo

About Akers Biosciences Stock (LON:AKR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
N/A
50-Day Range
57.50
57.50
52-Week Range
N/A
Volume
262 shs
Average Volume
818 shs
Market Capitalization
£21.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol 'Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth 'Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.

Remove Ads
Receive AKR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akers Biosciences and its competitors with MarketBeat's FREE daily newsletter.

AKR Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Headlines

AKR Stock Analysis - Frequently Asked Questions

Shares of AKR stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akers Biosciences investors own include SandRidge Permian Trust (PER), Rite Aid (RAD), AT&T (T), BP (BP), Cross Timbers Royalty Trust (CRT), Solbright Group (SBRT) and Workhorse Group (WKHS).

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
Trading
Current Symbol
LON:AKR
CIK
N/A
Fax
N/A
Employees
120
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
£2.32 million
Price / Cash Flow
0.90
Book Value
GBX 65.50 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
£21.64 million
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (LON:AKR) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners